ABVOCUS
DEAD

Serial Number

97518236

Owner

AADi Bioscience, Inc.

Attorney

Chelsea E. Carbone

Filing Date

Jul 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ABVOCUS Trademark

Serial Number: 97518236

ABVOCUS is a trademark filed by AADi Bioscience, Inc. on July 25, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

AADi Bioscience, Inc. (13 trademarks)

1343 Luna Vista Dr
Pacific Palisades, CA 90272

Entity Type: 03

Trademark Details

Filing Date

July 25, 2022

Registration Date

Not Registered

Published for Opposition

December 26, 2023

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in the treatment of diseases and disorders in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in pediatric, geriatric, emergency, family, and human preventative medicine for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease; pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease

Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of drug discovery process development, drug discovery validation, drug discovery qualification, and drug discovery manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation and testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation and testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 22, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 22, 2025 ABN6
ASSIGNED TO EXAMINER
Jul 15, 2025 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 4, 2025 EXRA
SOU EXTENSION 2 GRANTED
Feb 4, 2025 EX2G
SOU EXTENSION 2 FILED
Feb 3, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 3, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 2, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 2, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 2, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 2, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 20, 2024 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 8, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 8, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 8, 2024 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 26, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 26, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 6, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 21, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 21, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 21, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 21, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 21, 2023 CNEA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 25, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 25, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 26, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 26, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 26, 2023 CNRT
ASSIGNED TO EXAMINER
May 10, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 16, 2022 NWOS
NEW APPLICATION ENTERED
Jul 28, 2022 NWAP